Pharmaceutical company Eli Lilly has issued a warning about compounded versions of its blockbuster diabetes and weight-loss drugs tirzepatide (Mounjaro, Zepbound). According to Lilly’s research, these copycat formulations—often mixed with added vitamin B12—contain significant impurities that could pose safety risks to patients.
The findings, currently available as a preprint study that hasn’t been peer-reviewed, indicate that combining tirzepatide with vitamin B12 leads to the creation of a novel molecule. This new compound’s effects on the body are unknown, raising concerns about its potential impact on drug absorption, metabolism, toxicity, and immune responses. Lilly has notified the FDA and advises patients using these compounded drugs to consult with their doctors.
Why This Matters: The Risk of Unvetted Medications
Compounded drugs are custom-made mixtures created by pharmacies, not rigorously tested by the FDA like approved pharmaceuticals. While sometimes necessary during shortages, their quality control is less strict, raising concerns about inconsistent potency and unexpected side effects. In this case, Lilly’s tests showed that some compounded samples contained as little as 43% of the labeled drug amount.
The addition of vitamin B12, a common practice among compounders, may be intended to address fatigue or enhance weight loss, but there is no scientific evidence to support these claims. Excessive B12 intake can even cause adverse effects like headaches, nausea, and vomiting.
Legal Loopholes and the Compounding Industry
Compounded GLP-1 medications gained popularity during shortages, when the FDA allowed their production. Though shortages have eased, some compounders continue to offer cheaper alternatives by adding vitamins or other ingredients—a legal workaround. This practice allows them to sidestep FDA regulations and market personalized formulations without rigorous safety testing.
Industry Response and What Patients Should Do
The Alliance for Pharmacy Compounding (APC) disputes Lilly’s claims, arguing that there’s no widespread trend of adverse events reported from compounded drugs. However, APC acknowledges the need for further investigation, particularly if the impurities originate from unregulated sources like med spas rather than licensed pharmacies.
For patients using compounded GLP-1s with B12, experts recommend discussing alternatives with their healthcare provider. Affordable, FDA-approved options may be available for conditions like diabetes or sleep apnea. Additionally, the price gap between branded and compounded medications has narrowed, making legal alternatives more accessible.
Ultimately, this situation highlights the risks of relying on unapproved medications. While compounding pharmacies serve a purpose, patients should prioritize FDA-vetted treatments whenever possible to ensure safety and efficacy.
